At a median follow-up of 80 months
Over 5 years median overall survival for first-line postmenopausal patients with an AI1
Overall survival improved with a 24% reduction in risk of death1
KISQALI is the only CDK4/6 inhibitor with statistically significant overall survival proven in postmenopausal patients with an AI1-3
- MONALEESA-2: N=668, 1:1 randomization. As 1L in advanced disease. KISQALI 600 mg or placebo once daily (3 weeks on/1 week off) + letrozole 2.5 mg. Statistical significance was established in the first interim analysis (HR=0.56 [95% CI: 0.43-0.72]; P<0.0001). In an updated analysis, mPFS (primary end point) was 25.3 months for KISQALI + letrozole vs 16.0 months for placebo + letrozole (HR=0.57 [95% CI: 0.46-0.70]; P<0.0001)4-6
Wolfgang Janni, MD
University of Ulm
Ulm, Germany
Dr Wolfgang Janni talks about how KISQALI® (ribociclib) sets a new treatment standard with the latest MONALEESA-2 OS data.
David A. Cameron, MD
Edinburgh Cancer Research Centre
Edinburgh, UK
Dr David Cameron discusses what the latest OS data from the KISQALI® (ribociclib) MONALEESA-2 trial can mean for your patients.
Gabriel Hortobagyi, MD
MD Anderson Cancer Center
Houston, TX
Dr Gabriel Hortobagyi discusses how the latest OS data with KISQALI from MONALEESA-2 has the potential to be practice changing.